ArticleScientific reports2025
Metabolomics reveals the mechanism of Zhilong Huoxue Tongyu capsule in the treatment of heart failure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Energy deprivation in cardiomyocytes is a pivotal factor in the progression of heart failure (HF). Zhilong Huoxue Tongyu capsule (ZL) is a widely used Chinese patent medicine that has been employed in the treatment of various cardiovascular diseases. However, its effects on HF and its impact on cardiac metabolism remain to be elucidated. This study aims to validate the therapeutic effects of ZL on heart failure and analyze its influence on human cardiac metabolism through clinical trials and untargeted metabolomics research. A cohort of 80 HF patients was enrolled, all of whom received conventional treatment (CT) in conjunction with ZL. Primary therapeutic endpoints included left ventricular ejection fraction, brain natriuretic peptide levels, 6-min walking distance, the Minnesota Living with Heart Failure Questionnaire score, and traditional Chinese medicine (TCM) syndrome scores. Ultra-high performance liquid chromatography-tandem mass spectrometry was utilized to identify key compounds, core targets, and pathways implicated in the anti-HF effects of CT combined with ZL. Seventy-six subjects completed the clinical study. Post-treatment, significant improvements were observed in heart function, exercise endurance, quality of life, and TCM syndrome scores. Untargeted metabolomics screening identified 57 differential metabolites in the serum of subjects pre- and post-treatment, including PC 20:2_20:2 and cyclic acid, among others. Of these, 25 metabolites were upregulated, while 32 were downregulated. Pathway analysis indicated that these differential metabolites were involved in riboflavin metabolism, the citrate cycle, alanine, aspartate and glutamate metabolism, arginine biosynthesis, butanoate metabolism, lipoic acid metabolism, and fatty acid biosynthesis. The combination of CT and ZL for HF treatment exhibits promising clinical efficacy, potentially mediated through the optimization of cardiac energy metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.